Brent A. Hanks

Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?

John H. Strickler, Brent A. Hanks, Mustafa Khasraw · Clinical Cancer Research · 2020 · 405 citations · Full text

Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line Therapy

Paul Nghiem, Shailender Bhatia, Evan J. Lipson et al. · Journal of Clinical Oncology · 2019 · 386 citations · Full text

Paracrine Wnt5a-β-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization

Fei Zhao, Christine Xiao, Kathy S. Evans et al. · Immunity · 2018 · 287 citations · Full text

Signal Transduction, Signaling Pathway, Molecular Pathway +12

A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti–PD-1 immunotherapy

Balamayoora Theivanthiran, Kathy S. Evans, Nicholas C. DeVito et al. · Journal of Clinical Investigation · 2020 · 235 citations · Full text

Immunology, Immunotherapy Resistance, Immunotherapeutics +19

Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy

Alisha Holtzhausen, Fei Zhao, Kathy S. Evans et al. · Cancer Immunology Research · 2015 · 175 citations · Full text

T-regulatory Cell, Immunology, Immune Regulation +25